As the cellular and humoral alterations in LPS-induced colitis are similar to the changes seen in IBD, especially during the initiation of the disease (27) and in its acute exacerbations, T cell-specific PARP2 inhibition might be beneficial in these conditions. This evidence concerns the gene PARP2 and inflammatory bowel disease.